Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome

Summary

The purpose of this prospective, international phase III/IV study is to assess the efficacy and safety of metyrapone in patients with endogenous Cushing's syndrome during up to 36 weeks of treatment. The ability of metyrapone (250 mg capsules) to normalize urinary free cortisol (UFC) levels will be assessed during up to 36 weeks (9 months) of treatment.

Timeline

Start

2015-04

Primary completion

2019-11

Completion

2020-04-29

Drugs

Indications